Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

Objective Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of variability in ...

Objectives Ethnicity and health outcomes are intrinsically interrelated, although mechanisms are complex. SLE is a disease ...

Background SLE is a systemic autoimmune disease with a large number of common risk gene variants, but several rare gene ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...